Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

ASCUS LSIL Triage Study (ALTS) Conclusions Reaffirmed: Response to a November 2001 Commentary

Solomon, Diane MD; Schiffman, Mark MD, MPH; Tarone, Robert PhD

CURRENT COMMENTARY
Buy

ALTS investigators respond to a review of the trial data and reaffirm the conclusion that human papillomavirus testing is a viable option for the management of atypical squamous cells of undetermined significance.

Divisions of Cancer Prevention and Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

Address reprint requests to: Diane Solomon, MD, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2130, MSC 7333, 6130 Executive Boulevard, Bethesda, MD 20892–7333; E-mail: ds87v@nih.gov.

ALTS was supported by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services contracts CN-55153, CN-55154, CN-55155, CN-55156, CN-55157, CN-55158, CN-55159, and CN-55105. The following companies have provided support in the form of equipment or supplies at reduced or no cost: Cytyc Corporation, Boxborough, MA; DenVu, Tucson, AZ; National Testing Laboratories, Fenton, MO; Digene Corporation, Gaithersburg, MD; and TriPath Imaging, Elon, NC.

Members of the ALTS Group: University of Alabama at Birmingham, AL, E.E. Partridge, Principal Investigator, L. Kilgore, Co-Principal Investigator, S. Hester, Study Manager; University of Oklahoma, Oklahoma City, OK, J.L. Walker, Principal Investigator, G.A. Johnson, Co-Principal Investigator, A. Yadack, Study Manager; Magee-Womens Hospital of the University of Pittsburgh Medical Center Health System, Pittsburgh, PA, R.S. Guido, Principal Investigator, K. McIntyre-Seltman, Co-Principal Investigator, R.P. Edwards, Investigator, J. Gruss, Study Manager; University of Washington, Seattle, WA, N.B. Kiviat, Co-Principal Investigator, L. Koutsky, Co-Principal Investigator, C. Mao, Investigator; Colposcopy Quality Control Group, J.T. Cox, Co-Investigator, University of California at Santa Barbara, Santa Barbara, CA; HPV Quality Control Group, C.M. Wheeler, Principal Investigator, University of New Mexico Health Sciences Center, Albuquerque, NM, C. Peyton-Goodall, Lab Manager, University of New Mexico Health Sciences Center, Albuquerque, NM; Pathology Quality Control Group, R.J. Kurman, Principal Investigator, Johns Hopkins Hospital, Baltimore, MD, D.L. Rosenthal, Co-Investigator, Johns Hopkins Hospital, Baltimore, MD, M.E. Sherman, Co-Investigator, Johns Hopkins Hospital, Baltimore, MD, M.H. Stoler, Co-Investigator, University of Virginia Health Science Center, Charlottesville, VA; Cost Utility Analysis Group, D.M. Harper, Investigator, Dartmouth Hitchcock Medical Center, Lebanon, NH; Westat, Coordinating Unit, Rockville, MD, J. Rosenthal, Project Director, M. Dunn, Data Management Team Leader, J. Quarantillo, Senior Systems Analyst, D. Robinson, Clinical Center Coordinator.

Received December 14, 2001. Received in revised form January 16, 2002. Accepted January 17, 2002

© 2002 The American College of Obstetricians and Gynecologists